Medanta IPO – In order to acquire money through an IPO, Global Health Limited, which runs and manages hospitals under the Medanta brand, has submitted preliminary paperwork to SEBI.
A fresh issue of equity shares worth Rs 500 crore and an offer for sale (OFS) of up to 4.84 crore equity shares make up the first public offering (IPO).
Anant Investments, a subsidiary of the large private equity firm Carlyle Group, will sell up to 4.33 crore equity shares as part of the OFS, while Global Health co-founder Sunil Sachdeva will sell up to 51 lakh equity shares jointly with Suman Sachdeva.
The book running lead managers for the IPO are KotaK Mahindra Capital Company, Credit Suisse Securities (India), Jefferies India, and JM Financial.
About Medanta | Global Health Limited
One of the biggest private, multi-specialty tertiary care providers in India’s North and East is Global Health Limited. Global Health, founded by Naresh Trehan, a renowned cardiovascular and cardiothoracic surgeon, is a leading private multi-speciality tertiary care providers in the north and east regions of India with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology.
Dr. Trehan has been awarded the prestigious Padma Bhushan and the Padma Shri, the third and fourth-highest civilian awards in India, and the BC Roy Award, in recognition of his distinguished contribution to medicine. Under the “Medanta” brand, the firm has a network of four operational hospitals in Gurugram, Indore, Ranchi and Lucknow, a hospital which is under construction with an operational outpatient facility in Patna, and one hospital in Noida is planned for development.
It provides healthcare services in over 30 medical specialties and engage over 1,100 doctors led by highly experienced department heads and operational hospitals have 2,176 installed beds. The Indian healthcare delivery industry is estimated to post a healthy 15-17% CAGR between FY21 and FY25 driven by pent up demand, strong fundamentals, and increasing affordability. In 2019, the firm had 1,722 installed beds, which grew to 2,176 installed beds by 2021, representing a growth of 26.36%. Upon operation of the in-patient department at the Patna hospital in FY 2022 and Noida hospital in FY 2025, the number of total installed beds is expected to exceed 3,500 at the end of FY2025 which will cater to domestic and international patients as part of the business strategy to capitalize on medical tourism.
Competitive Strength of Medanta
1-Leading supplier of tertiary and quaternary care in India, highly known for its clinical proficiency, particularly in handling challenging situations.
2-Concentrate on academics and clinical research.
3- large hospitals with top-notch facilities, modern medical technology, and equipment.
4- Strong operational and financial performance history.
5-Concentrate on underserved areas with high population densities, and be present in the largest or capital cities of big states (NCR, Lucknow and Patna).
6-Possibilities for expansion in already-built facilities and diversification into new services, like digital health.
7- senior management team with extensive experience and strong institutional shareholder support.
DCX Systems IPO- Should you Invest or avoid ?
Financial Detail of Medanta | Global Health Ltd
|
Particulars (in Rs. Crores) |
FY21 |
FY20 |
FY19 |
|
Revenue |
1,446.74 |
1,500.42 |
1,455.80 |
|
EBITDA |
222.85 |
230.45 |
217.90 |
|
PAT |
28.81 |
36.33 |
51.30 |
|
EPS (basic in Rs.) |
1.15 |
1.45 |
2.06 |
|
ROE |
2.08% |
2.69% |
3.96% |
|
ROCE |
5.10% |
6.90% |
– |
|
Particulars (in Rs. Crores) |
FY21 |
FY20 |
FY19 |
|
Total Assets |
2,694.11 |
2,666.29 |
2,430.01 |
|
Share Capital |
49.59 |
49.35 |
49.13 |
|
Total Borrowings |
644.60 |
621.94 |
513.73 |
|
Particulars (in Rs. Crores) |
FY21 |
FY20 |
FY19 |
|
Net cash generated from / (used in) operating activities |
241.77 |
175.07 |
165.55 |
|
Net cash from / (used in) investing activities |
-239.15 |
-87.07 |
-248.76 |
|
Net cash flow from / (used in) financing activities |
-80.72 |
-0.88 |
97.03 |
|
Net increase (decrease) in cash and cash equivalents |
-78.11 |
87.12 |
13.83 |
Medanta IPO | Global Health IPO Tentative Timetable
| Event | Tentative Date |
|---|---|
| Opening Date | Nov 3, 2022 |
| Closing Date | Nov 7, 2022 |
| Basis of Allotment | Nov 11, 2022 |
| Initiation of Refunds | Nov 14, 2022 |
| Credit of Shares to Demat | Nov 15, 2022 |
| Listing Date | Nov 16, 2022 |
Objective of Medanta IPO | Global Health Limited IPO
The company proposes to utilize the net proceeds of the Fresh Issue towards funding of the following objects:
1. Repayment/prepayment of borrowings, in full or part, of the Subsidiaries, GHPPL and MHPL.
2. General corporate purposes.
Global Health IPO | Medanta IPO Details
| IPO Date | Nov 3, 2022 to Nov 7, 2022 |
| Listing Date | [16-Nov-2022] |
| Face Value | ₹2 per share |
| Price | [319] to [336] per share |
| Lot Size | 44 Shares |
| Issue Size | (aggregating up to ₹2,205.57 Cr) |
| Fresh Issue | [.] shares of ₹2 (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 50,761,000 shares of ₹2 (aggregating up to ₹[1705.57] Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | Not more than 50% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| Company Promoters | Dr. Naresh Trehan is the company promoter. |
Risk factors in Medanta IPO | Global Health Limited IPO
1. Stringent restrictions to slow down the spread of Covid-19, including limitations on international and local travel.
2. Highly dependent on doctors, nurses and other healthcare professionals thus, failure to retain or attract staff may hurt business.
3. Failure to pass on high costs such as manpower cost, infrastructure maintenance and repair cost, high medical equipment cost to the patients.
4. Developing or to be developed facilities may experience delays in construction, in reaching full operational capacity.
5. Certain land parcels on which the hospital buildings and clinics operate are neither owned by us nor leased to us on a perpetual basis.
6. Regulatory reforms in the healthcare industry and associated uncertainty.
Global Health IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: [email protected]
Website: https://karisma.kfintech.com/
Global Health IPO | Medanta IPO Prospectus
Company Contact Information
Medanta – Mediclinic,
E-18, Defence Colony,
New Delhi, Delhi 110 024,
Phone: +91 124 483 4060
Email: [email protected]
Website: https://www.medanta.org/
How to buy Medanta IPO| Global Health Limited online through Zerodha?
If you do not have Zerodha account, sign-up here and proceed to the next step.
If you have a demat account with Zerodha, you can apply this IPO online using the UPI as a payment gateway. Zerodha customers can apply in this IPO by login into Zerodha Console submitting an IPO application form.
1) Visit the Zerodha portal and login to the console.
2) Go to Portfolio and click the IPOs link.
3) Visit ‘Tracxn Technologies Limited IPO’ row and click the ‘Bid’ button.
4) Enter your UPI ID, Qty and the Price which you want to bid.
5) Click on ‘Submit’ IPO application form.
6) Visit the UPI App (net banking or BHIM) to approve the mandate.
You can follow us on
- Facebook – Click Here
- Twitter – Click here
- Telegram – Click Here
- Instagram – Click Here
Open your Demat account with Below Brokers
– 
– 
– 
– 